Results 281 to 290 of about 61,821 (357)

Elranatamab Versus Teclistamab in Relapsed and Refractory Multiple Myeloma: A Real-World Propensity Score-Matched Study. [PDF]

Target Oncol
Wang YC, Li PH, Lin CH, Su YC, Teng CJ.
europepmc   +1 more source

The Year of the Bispecific

The Hematologist
openaire   +1 more source

B‐Lymphoblastic Leukemia With Isolated Central Nervous System Relapse Mimicking a Vestibular Schwannoma

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT The central nervous system (CNS) is the most common site of extramedullary relapse in acute lymphoblastic leukemia (ALL). However, the diagnosis may be challenging due to its protean manifestations. A 64‐year‐old male reported right‐sided hearing loss with intermittent bilateral occipitotemporal headaches during a clinic follow‐up for Ph + B ...
Jun Yen Ng, Shivendra T. Lalloo, Samuel Milliken, Mark N. Polizzotto   +3 more
wiley   +1 more source

Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.

Blood
Ren H, Elliott N, Lye B, Sharif Shohan MU, Cross JW, Field L, Ponnusamy K, Rice S, Jackson T, Leontari I, El Ouazzani N, Thomas R, Inglott S, Bartram J, Smith O, Bond J, Roberts IAG, Halsey C, Bashford-Rogers R, Milne TA, Roy A, Karadimitris A.   +21 more
europepmc   +1 more source

2026 Update on the Management of Diffuse Large B-Cell Lymphoma. [PDF]

Am J Hematol
Chong EA, Tomasulo EB, Barta SK.
europepmc   +1 more source

Molecular Structures and Molecular Interactions of Peptides and Proteins at Buried Interfaces Studied Using Sum Frequency Generation Vibrational Spectroscopy

Chemistry–Methods, Volume 6, Issue 5, May 2026.
This review provides a detailed record of recent advances in the field of determining protein conformation and orientation on various interfaces using sum frequency generation vibrational spectroscopy. We delve deep into how the addition of the Hamiltonian spectral matching formalism, isotope labeling, and Molecular Dynamics simulations has allowed us ...
Zahra Asif Gandhi, Kapil Shrawankar, Zhan Chen   +2 more
wiley   +1 more source

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders. [PDF]

Cells
Yasui H, Idogawa M, Ishida T, Imai K.
europepmc   +1 more source

Figure 5 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

Charlotte J. Imianowski, Paula Kuo, Sarah K. Whiteside, Teresa von Linde, Alexander J. Wesolowski, Alberto G. Conti, Alexander C. Evans, Tarrion Baird, Benjamin I. Morris, Nicole E. Fletcher, Jie Yang, Edmund Poon, Matthew A. Lakins, Masahiro Yamamoto, Neil Brewis, Michelle Morrow, Rahul Roychoudhuri   +16 more
openalex   +1 more source

Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein

Chemistry–Methods, Volume 6, Issue 5, May 2026.
The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley, Joshua D. Bryant, Samuel Vrana, Karuppiah Chockalingam, Zhilei Chen   +4 more
wiley   +1 more source